Paul Tudor Jones’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Paul Tudor Jones’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,249	Closed	-$464K	–	3983
2025 Q4	$464K	Sell	11,249 -6,642	-37%	-$266K	﹤0.01%	2762
2025 Q3	$695K	Sell	17,891 -3,212	-15%	-$104K	﹤0.01%	2508
2025 Q2	$584K	Buy	21,103 +482	+2%	+$12.3K	﹤0.01%	2495
2025 Q1	$458K	Buy	+20,621	New	+$424K	﹤0.01%	2334
2024 Q4	–	Sell	-20,235	Closed	-$506K	–	3282
2024 Q3	$506K	Buy	+20,235	New	+$493K	﹤0.01%	2027

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Paul Tudor Jones's KNSA Position: Q1 2026 in Review

Paul Tudor Jones sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 11,249 shares — an estimated $464K sold.

Paul Tudor Jones first reported a position in KNSA in Q3 2024 and held it in 5 quarters. The position peaked at $695K in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Paul Tudor Jones reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 11,249 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $464K.
Paul Tudor Jones first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Paul Tudor Jones's Kiniksa Pharmaceuticals position peaked at $695K in Q3 2025.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.